Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 1:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Netherton Syndrome Clear all

Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725

NCT06539507

View directory record Official record

Conditions: Netherton Syndrome
Interventions: BCX17725, Placebo; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 12 Years to 65 Years

Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Palo Alto, California • San Diego, California • New Haven, Connecticut + 2 more

Source: ClinicalTrials.gov public record

Updated May 17, 2026 · Synced May 22, 2026, 1:30 AM EDT

Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Defining the Skin and Blood Biomarkers of Ichthyosis

NCT03417856

View directory record Official record

Conditions: Ichthyosis, Netherton Syndrome
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 1 Year to 60 Years

Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 4
States / cities: Chicago, Illinois • New York, New York

Source: ClinicalTrials.gov public record

Updated Apr 26, 2026 · Synced May 22, 2026, 1:30 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects

NCT05388903

View directory record Official record

Conditions: Netherton Syndrome
Interventions: DS-2325a, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 45 Years

Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Mar 5, 2023 · Synced May 22, 2026, 1:30 AM EDT

Active, not recruiting Phase 2Phase 3 Interventional

Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

NCT05521438

View directory record Official record

Conditions: Netherton Syndrome
Interventions: QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle, QRX003-4% Lotion BID; Drug
Lead sponsor: Quoin Pharmaceuticals; Industry
Eligibility: 14 Years and older

Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 5
States / cities: San Diego, California • Indianapolis, Indiana • Quincy, Massachusetts + 2 more

Source: ClinicalTrials.gov public record

Updated Mar 15, 2026 · Synced May 22, 2026, 1:30 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects

NCT05583669

View directory record Official record

Conditions: Netherton Syndrome
Interventions: DS-2325a, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 50 Years

Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Source: ClinicalTrials.gov public record

Updated May 17, 2023 · Synced May 22, 2026, 1:30 AM EDT

Recruiting Phase 2Phase 3 Interventional

Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

NCT06953466

View directory record Official record

Conditions: Netherton Syndrome
Interventions: QRX003, 4% Lotion; Drug
Lead sponsor: Quoin Pharmaceuticals; Industry
Eligibility: 14 Years and older

Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Source: ClinicalTrials.gov public record

Updated Jul 19, 2025 · Synced May 22, 2026, 1:30 AM EDT

Recruiting Phase 1 Interventional

Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome

NCT06137157

View directory record Official record

Conditions: Netherton Syndrome
Interventions: ATR12-351; Drug
Lead sponsor: Azitra Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Palo Alto, California • New Haven, Connecticut

Source: ClinicalTrials.gov public record

Updated Feb 4, 2026 · Synced May 22, 2026, 1:30 AM EDT

Recruiting Phase 2Phase 3 Interventional

Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome

NCT05789056

View directory record Official record

Conditions: Netherton Syndrome
Interventions: QRX003, 4% Lotion; Drug
Lead sponsor: Quoin Pharmaceuticals; Industry
Eligibility: 14 Years and older

Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 4
States / cities: San Diego, California • Indianapolis, Indiana • Quincy, Massachusetts + 1 more

Source: ClinicalTrials.gov public record

Updated Apr 1, 2025 · Synced May 22, 2026, 1:30 AM EDT

Terminated Phase 2Phase 3 Interventional Results available

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome

NCT05856526

View directory record Official record

Conditions: Netherton Syndrome
Interventions: Spesolimab - solution for infusion, Placebo matching to spesolimab - solution for infusion, Spesolimab - solution for injection, Placebo matching to spesolimab - solution for injection; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years and older

Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 4
States / cities: Rancho Santa Margarita, California • New Haven, Connecticut • Charleston, South Carolina + 1 more

Source: ClinicalTrials.gov public record

Updated Mar 11, 2026 · Synced May 22, 2026, 1:30 AM EDT

Recruiting Phase 2Phase 3 Interventional

Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

NCT07538583

View directory record Official record

Conditions: Netherton Syndrome
Interventions: QRX003; Drug
Lead sponsor: Quoin Pharmaceuticals; Industry
Eligibility: 4 Years and older

Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Fremont, California • New Haven, Connecticut • Indianapolis, Indiana + 2 more

Source: ClinicalTrials.gov public record

Updated Apr 20, 2026 · Synced May 22, 2026, 1:30 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome

NCT01428297

View directory record Official record

Conditions: Healthy Volunteers, Atopic Dermatitis, Netherton Syndrome
Interventions: BPR277 ointment (controlled application), Placebo (Vehicle), BPR277 ointment, BPR277; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: New Haven, Connecticut • St Louis, Missouri • Fargo, North Dakota

Source: ClinicalTrials.gov public record

Updated Dec 7, 2020 · Synced May 22, 2026, 1:30 AM EDT

Completed Phase 1Phase 2 Interventional Results available

Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome

NCT00208026

View directory record Official record

Conditions: Netherton Syndrome
Interventions: Pimecrolimus 1% Cream; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years to 18 Years

Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Source: ClinicalTrials.gov public record

Updated Aug 13, 2019 · Synced May 22, 2026, 1:30 AM EDT

Terminated No phase listed Observational

Natural History of Netherton Syndrome

NCT05902663

View directory record Official record

Conditions: Netherton Syndrome
Interventions: Not listed
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: Not listed

Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Rancho Santa Margarita, California • Chicago, Illinois • Philadelphia, Pennsylvania

Source: ClinicalTrials.gov public record

Updated Oct 9, 2025 · Synced May 22, 2026, 1:30 AM EDT

Completed Phase 2 Interventional Results available

The Efficacy and Safety of Secukinumab in Patients With Ichthyoses

NCT03041038

View directory record Official record

Conditions: Ichthyosis, Autosomal Recessive Congenital Ichthyosis, Lamellar Ichthyosis, Congenital Ichthyosiform Erythroderma, Epidermolytic Ichthyosis, Netherton Syndrome
Interventions: Secukinumab, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older

Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Source: ClinicalTrials.gov public record

Updated Aug 24, 2021 · Synced May 22, 2026, 1:30 AM EDT